Validate diagnostic markers
Evaluate existing clinical, imaging, and blood-based measures that may help distinguish LATE from other causes of cognitive change.
Study design, cohort goals, eligibility, measures, and participating sites for a multi-site effort to improve detection and trial readiness for LATE.
The study is designed to improve recognition of LATE during life, discover biomarkers, and prepare the field for future clinical trials.
Evaluate existing clinical, imaging, and blood-based measures that may help distinguish LATE from other causes of cognitive change.
Use longitudinal data and biospecimens to identify new markers that can support research and future clinical use.
Build the evidence needed to identify appropriate participants and outcomes for future LATE-focused trials.
Eligibility is determined by study staff. The details below summarize the primary pathways for researchers and referring clinicians.
Adults age 85 and older with a range of cognitive and MRI characteristics relevant to the discovery cohort.
Adults age 75 and older with cognitive impairment or dementia who are amyloid negative may be eligible for a targeted pathway.
Participants complete annual visits and selected remote measures to support a detailed picture of cognition and biomarker change over time.
Each center contributes clinical expertise and research infrastructure to a shared longitudinal cohort.
Contact the TRC-LATE Study team for site-specific questions, eligibility information, or research collaboration.